Thomas O. Bergmeijer

2.1k total citations · 2 hit papers
33 papers, 1.1k citations indexed

About

Thomas O. Bergmeijer is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Thomas O. Bergmeijer has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Cardiology and Cardiovascular Medicine, 21 papers in Surgery and 9 papers in Internal Medicine. Recurrent topics in Thomas O. Bergmeijer's work include Antiplatelet Therapy and Cardiovascular Diseases (30 papers), Acute Myocardial Infarction Research (16 papers) and Coronary Interventions and Diagnostics (10 papers). Thomas O. Bergmeijer is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (30 papers), Acute Myocardial Infarction Research (16 papers) and Coronary Interventions and Diagnostics (10 papers). Thomas O. Bergmeijer collaborates with scholars based in Netherlands, United States and United Kingdom. Thomas O. Bergmeijer's co-authors include Jurriën M. ten Berg, Vera H.M. Deneer, Johannes C. Kelder, Paul W.A. Janssen, Arnoud W.J. van ‘t Hof, Folkert W. Asselbergs, Willem J.M. Dewilde, Jean‐Paul R. Herrman, Daniel M.F. Claassens and Maarten J. Postma and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Thomas O. Bergmeijer

30 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI

2019 378 citations Daniel M.F. Claassens, Gerrit J.A. Vos et al. New England Journal of Medicine profile →
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

2020 212 citations Marieke E. Gimbel, Laura M. Willemsen et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas O. Bergmeijer Netherlands	15	1.0k	513	280	148	84	33	1.1k
Paul W.A. Janssen Netherlands	14	693 0.7×	354 0.7×	202 0.7×	77 0.5×	75 0.9×	30	792
Willem J.M. Dewilde Netherlands	9	1.6k 1.5×	488 1.0×	456 1.6×	75 0.5×	69 0.8×	19	1.7k
Daniel M.F. Claassens Netherlands	8	442 0.4×	237 0.5×	118 0.4×	75 0.5×	67 0.8×	16	517
Chantal Pharand Canada	15	831 0.8×	345 0.7×	229 0.8×	119 0.8×	36 0.4×	40	1.0k
Nicoline J. Breet Netherlands	18	1.7k 1.7×	831 1.6×	536 1.9×	283 1.9×	58 0.7×	28	1.8k
Ying G. Li United States	17	906 0.9×	448 0.9×	226 0.8×	370 2.5×	28 0.3×	21	1.2k
Thomas Cuisset France	22	2.0k 2.0×	1.2k 2.3×	386 1.4×	160 1.1×	39 0.5×	77	2.2k
Gerrit J.A. Vos Netherlands	6	381 0.4×	199 0.4×	99 0.4×	64 0.4×	63 0.8×	9	451
Ilaria Sestini Italy	10	413 0.4×	254 0.5×	62 0.2×	126 0.9×	47 0.6×	14	653
Bonnie L. Hiatt United States	6	1.3k 1.3×	687 1.3×	382 1.4×	164 1.1×	29 0.3×	9	1.4k

Countries citing papers authored by Thomas O. Bergmeijer

Since Specialization

Citations

This map shows the geographic impact of Thomas O. Bergmeijer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas O. Bergmeijer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas O. Bergmeijer more than expected).

Fields of papers citing papers by Thomas O. Bergmeijer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas O. Bergmeijer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas O. Bergmeijer. The network helps show where Thomas O. Bergmeijer may publish in the future.

Co-authorship network of co-authors of Thomas O. Bergmeijer

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas O. Bergmeijer. A scholar is included among the top collaborators of Thomas O. Bergmeijer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas O. Bergmeijer. Thomas O. Bergmeijer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bergmeijer, Thomas O., Dean R.P.P. Chan Pin Yin, Joyce Peper, et al.. (2022). Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study. Frontiers in Pharmacology. 13. 1032995–1032995. 2 indexed citations

Claassens, Daniel M.F., Renicus S. Hermanides, Gerrit J.A. Vos, et al.. (2021). Efficacy and safety of glycoproteinIIb/IIIainhibitors in addition toP2Y₁₂inhibitors inST‐segment elevation myocardial infarction: A subanalysis of thePOPularGenetics trial. Catheterization and Cardiovascular Interventions. 99(3). 676–685. 4 indexed citations

Claassens, Daniel M.F., Thomas O. Bergmeijer, Gerrit J.A. Vos, et al.. (2021). Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype. Circulation Cardiovascular Interventions. 14(4). 17 indexed citations

Claassens, Daniel M.F., Gerrit J.A. Vos, Thomas O. Bergmeijer, et al.. (2021). Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial. American Journal of Cardiovascular Drugs. 22(2). 195–206. 16 indexed citations

Bergmeijer, Thomas O., Gerrit J.A. Vos, Paul W.A. Janssen, et al.. (2020). Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. Genes. 11(9). 1068–1068. 1 indexed citations

Angiolillo, Dominick J., Davide Capodanno, Nicolas Danchin, et al.. (2020). Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel. JACC: Cardiovascular Interventions. 13(5). 606–617. 94 indexed citations

Gimbel, Marieke E., Laura M. Willemsen, Rik Hermanides, et al.. (2020). Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. The Lancet. 395(10233). 1374–1381. 212 indexed citations breakdown →

Claassens, Daniel M.F., Gerrit J.A. Vos, Thomas O. Bergmeijer, et al.. (2019). A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI. New England Journal of Medicine. 381(17). 1621–1631. 378 indexed citations breakdown →

Godschalk, Thea C., Marieke E. Gimbel, Giovanni Amoroso, et al.. (2018). A clinical risk score to identify patients at high risk of very late stent thrombosis. Journal of Interventional Cardiology. 31(2). 159–169. 5 indexed citations

10.

Godschalk, Thea C., Laura M. Willemsen, Bastiaan Zwart, et al.. (2017). Effect of Tailored Antiplatelet Therapy to Reduce Recurrent Stent Thrombosis and Cardiac Death After a First Episode of Stent Thrombosis. The American Journal of Cardiology. 119(10). 1500–1506. 2 indexed citations

11.

Bergmeijer, Thomas O., Paul W.A. Janssen, Thea C. Godschalk, et al.. (2017). Incidence and Causes for Early Ticagrelor Discontinuation: A “Real-World” Dutch Registry Experience. Cardiology. 138(3). 164–168. 23 indexed citations

12.

Heestermans, Antonius A.C.M., J. Wouter Jukema, Michiel Voskuil, et al.. (2015). Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older—rationale and design of the POPular AGE study. American Heart Journal. 170(5). 981–985.e1. 28 indexed citations

13.

Bergmeijer, Thomas O., Paul W.A. Janssen, Folkert W. Asselbergs, et al.. (2014). CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. American Heart Journal. 168(1). 16–22.e1. 60 indexed citations

14.

Bergmeijer, Thomas O., Udaya S. Tantry, Jurriën M. ten Berg, et al.. (2014). The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thrombosis and Haemostasis. 112(9). 589–597. 24 indexed citations

15.

Breet, Nicoline J., Willem Jan W. Bos, Heleen Bouman, et al.. (2014). The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. Thrombosis and Haemostasis. 112(12). 1174–1181. 22 indexed citations

16.

Bergmeijer, Thomas O., et al.. (2013). Ticagrelor is frequently discontinued in a real world setting. European Heart Journal. 34(suppl 1). P4867–P4867. 2 indexed citations

17.

Erlinge, David, Jurriën M. ten Berg, David P. Foley, et al.. (2012). PRASUGREL 5 MG IN LOW BODY WEIGHT PATIENTS REDUCES PLATELET REACTIVITY TO A SIMILAR EXTENT AS PRASUGREL 10 MG IN HIGHER BODY WEIGHT PATIENTS: RESULTS FROM THE FEATHER TRIAL. Journal of the American College of Cardiology. 59(13). E341–E341. 4 indexed citations

18.

Erlinge, David, Jurriën M. ten Berg, David P. Foley, et al.. (2012). Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients. Journal of the American College of Cardiology. 60(20). 2032–2040. 63 indexed citations

19.

Postma, Sonja, Thomas O. Bergmeijer, Jurriën M. ten Berg, & Arnoud W.J. van ‘t Hof. (2012). Pre-hospital diagnosis, triage and treatment in patients with ST elevation myocardial infarction. Heart. 98(22). 1674–1678.

20.

Bergmeijer, Thomas O., Jochem W. van Werkum, Udaya S. Tantry, Paul A. Gurbel, & Jurriën M. ten Berg. (2011). Platelet Function Testing in Clinical Practice – Experience and Views from Europe and the US. European Cardiology Review. 7(3). 203–203. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact